Study protocol: Safety and efficacy of smart watch integrated do-it-yourself continuous glucose monitoring in adults with Type 1 diabetes, a randomised controlled trial

Author(s):  
Shekhar Sehgal ◽  
Martin De Bock ◽  
Jonathan Williman ◽  
Barry Taylor ◽  
Mona Elbalshy ◽  
...  
2017 ◽  
Vol 221 (06) ◽  
pp. 260-261

Feig DS et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017; pii: S0140-6736(17)32400-5. doi:10.1016/S0140-6736(17)32400-5 Um das Risiko für maternale und fetale Komplikationen zu minimieren, sollen Typ-1-Diabetes-Patientinnen vor sowie während der Schwangerschaft auf eine optimale Blutzuckereinstellung achten. Dies gelingt jedoch nicht immer. Profitieren diese Frauen und ihre Kinder von einem kontinuierlichen Glukosemonitoring (CGM)? Ein internationales Forscherteam ist dieser Frage mithilfe einer randomisierten kontrollierten Studie nachgegangen.


BMJ Open ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. e036474
Author(s):  
Anna Lilja Secher ◽  
Ulrik Pedersen-Bjergaard ◽  
Ole Lander Svendsen ◽  
Birthe Gade-Rasmussen ◽  
Thomas P Almdal ◽  
...  

IntroductionThere are beneficial effects of advanced carbohydrate counting with an automatic bolus calculator (ABC) and intermittently scanned continuous glucose monitoring (isCGM) in persons with type 1 diabetes. We aim to compare the effects of isCGM, training in carbohydrate counting with ABC and the combination of the two concepts with standard care.Methods and analysisA multi-centre randomised controlled trial with inclusion criteria: ≥18 years, type 1 diabetes ≥1 year, injection therapy, HbA1c >53 mmol/mol, whereas daily use of carbohydrate counting and/or CGM/isCGM wear are exclusion criteria. Inclusion was initiated in October 2018 and is ongoing. Eligible persons are randomised into four groups: standard care, ABC, isCGM or ABC+isCGM. Devices used are FreeStyle Libre Flash and smart phone diabetes application mySugr. Participants attend group courses according to treatment allocation with different educational contents. Participants are followed for 26 weeks with clinical visits and telephone consultations. At baseline and at study end, participants wear blinded CGM, have blood samples performed and fill in questionnaires on person-related outcomes, and at baseline also on personality traits and hypoglycaemia awareness. The primary outcome is the difference in time spent in normoglycaemia (4–10 mmol/L) at study end versus baseline between the isCGM group and the standard care group. Secondary outcomes will also be analysed. Results are expected in 2020.Ethics and disseminationRegional Scientific Ethics Committee approval (H-17040573). Results will be sought disseminated at conferences and in high impact journals.Trial registration numberClinicalTrial.gov registry (NCT03682237).


Sign in / Sign up

Export Citation Format

Share Document